Jan-Erik Frödin

Publications
CV
Public outreach and news

Articles

Article: ACTA ONCOLOGICA. 2024;63:248-258
Detailed analysis of metastatic colorectal cancer patients who developed cardiotoxicity on another fluoropyrimidine and switched to S-1 treatment (subgroup analysis of the CardioSwitch-study)
Kinos S; Hagman H; Halonen P; Soveri L-M; O'Reilly M; Pfeiffer P; Froedin J-E; Sorbye H; Heerva E; Liposits G; Kallio R; Algars A; Ristamaki R; Salminen T; Barlund M; Shah C-H; Mcdermott R; Rockert R; Flygare P; Kwakman J; Teske AJ; Punt C; Glimelius B; Osterlund P
Article: EUROPEAN JOURNAL OF CANCER. 2024;202:114010
Fertility and reproductive concerns related to the new generation of cancer drugs and the clinical implication for young individuals undergoing treatments for solid tumors
Helgadottir H; Matikas A; Fernebro J; Frodin J-E; Ekman S; Rodriguez-Wallberg KA
Article: PLOS ONE. 2024;19(3):e0294018
Efficacy of hyperthermic intraperitoneal chemotherapy in colorectal cancer: A phase I and III open label randomized controlled registry-based clinical trial protocol
Ghanipour L; Palmer GJ; Nilsson PJ; Nordenvall C; Frodin J-E; Bexe Lindskog E; Asplund D; Swartling T; Graf W; Birgisson H; Syk I; Verwaal V; Brandstedt J; Cashin PH
Article: ESMO OPEN. 2023;8(2):101158
The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancerdresults from the RAPIDO trial
Dijkstra EA; Zwart WH; Nilsson PJ; Putter H; Roodvoets AGH; Kranenbarg EM-K; Froedin JE; Nygren P; ostergaard L; Kersten C; Verbiene I; Cervantes A; Hendriks MP; Capdevila J; Edhemovic I; van de Velde CJH; Marijnen CAM; van Etten B; Hospers GAP; Glimelius B
Article: CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY. 2023;39:100562
Preoperative short-course radiation therapy with PROtons compared to photons in high-risk RECTal cancer (PRORECT): Initial dosimetric experience
Pedone C; Sorcini B; Staff C; Farlin J; Fokstuen T; Frodin J-E; Nilsson PJ; Martling A; Valdman A
Article: CANCERS. 2022;14(24):6238
Associations between Response to Commonly Used Neo-Adjuvant Schedules in Rectal Cancer and Routinely Collected Clinical and Imaging Parameters
Karimi M; Osterlund P; Hammarstroem K; Imam I; Frodin J-E; Glimelius B
Article: ESMO OPEN. 2022;7(3):100427
Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study
Osterlund P; Kinos S; Pfeiffer P; Salminen T; Kwakman JJM; Frodin J-E; Shah CH; Sorbye H; Ristamaki R; Halonen P; Soveri LM; Heerva E; Algars A; Barlund M; Hagman H; McDermott R; O'Reilly M; Rockert R; Liposits G; Kallio R; Flygare P; Teske AJ; van Werkhoven E; Punt CJA; Glimelius B
Article: BJS OPEN. 2021;5(6):zrab137
Radiotherapy regimens for rectal cancer: long-term outcomes and health-related quality of life in the Stockholm III trial
Erlandsson J; Fuentes S; Radu C; Frodin J-E; Johansson H; Brandberg Y; Holm T; Glimelius B; Martling A
Article: JOURNAL OF PATIENT-REPORTED OUTCOMES. 2021;5(1):58
Quality of life assessments in clinical practice using either the EORTC-QLQ-C30 or the SEIOQL-DW: a randomized study
Kettis A; Fagerlind H; Frodin J-E; Glimelius B; Ring L
Article: EUROPEAN JOURNAL OF SURGICAL ONCOLOGY. 2018;44(7):983-990
Quality of life and cost effectiveness in a randomized trial of patients with colorectal cancer and peritoneal metastases
Cashin PH; Mahteme H; Syk I; Frodin JE; Glimelius B; Graf W
Article: ANNALS OF SURGERY. 2018;267(2):326-331
Risk of Acute Testicular Failure After Preoperative Radiotherapy for Rectal Cancer: A Prospective Cohort Study
Buchli C; Martling A; Al Abani M; Frodin J-E; Bottai M; Lax I; Arver S; Holm T
Article: HEREDITARY CANCER IN CLINICAL PRACTICE. 2018;16:16
A retrospective study of extracolonic, non-endometrial cancer in Swedish Lynch syndrome families
Karimi M; von Salome J; Aravidis C; Silander G; Askmalm MS; Henriksson I; Gebre-Medhin S; Frodin J-E; Bjorck E; Lagerstedt-Robinson K; Lindblom A; Tham E
Article: INTERNATIONAL JOURNAL OF CANCER. 2017;140(2):431-439
Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial
Sclafani F; Kim TY; Cunningham D; Kim TW; Tabernero J; Schmoll HJ; Roh JK; Kim SY; Park YS; Guren TK; Hawkes E; Clarke SJ; Ferry D; Frodin J-E; Ayers M; Nebozhyn M; Peckitt C; Loboda A; Watkins DJ
Article: PANCREATOLOGY. 2016;16(4):640-645
A phase I dose escalation trial of AXP107-11, a novel multi-component crystalline form of genistein, in combination with gemcitabine in chemotherapy-naive patients with unresectable pancreatic cancer
Lohr J-M; Karimi M; Omazic B; Kartalis N; Verbeke CS; Berkenstam A; Frodin J-E
Article: ACTA ONCOLOGICA. 2016;55(4):496-501
Assessment of testicular dose during preoperative radiotherapy for rectal cancer
Buchli C; Al Abani M; Ahlberg M; Holm T; Fokstuen T; Bottai M; Frodin J-E; Lax I; Martling A
Article: EUROPEAN JOURNAL OF CANCER. 2016;53:155-162
Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial
Cashin PH; Mahteme H; Spang N; Syk I; Frodin JE; Torkzad M; Glimelius B; Graf W
Article: ACTA ONCOLOGICA. 2016;55(2):140-148
A novel oral insulin-like growth factor-1 receptor pathway modulator and its implications for patients with non-small cell lung carcinoma: A phase I clinical trial
Ekman S; Harmenberg J; Frodin J-E; Bergstrom S; Wassberg C; Eksborg S; Larsson O; Axelson M; Jerling M; Abrahmsen L; Hedlund A; Alvfors C; Stahl B; Bergqvist M
Article: ANNALS OF ONCOLOGY. 2016;27(1):140-147
A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial
Hagman H; Frodin J-E; Berglund A; Sundberg J; Vestermark LW; Albertsson M; Fernebro E; Johnsson A
Article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2015;107(12):djv258
A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer
Sclafani F; Kim TY; Cunningham D; Kim TW; Tabernero J; Schmoll HJ; Roh JK; Kim SY; Park YS; Guren TK; Hawkes E; Clarke SJ; Ferry D; Frodin J-E; Ayers M; Nebozhyn M; Peckitt C; Loboda A; Mauro DJ; Watkins DJ
Article: ACTA ONCOLOGICA. 2015;54(7):1056-1062
Why is intravenous chemotherapy cancelled and how often. Could it be prevented? A prospective analysis of all planned and given intravenous anti-tumor treatments at the Department of Oncology, Karolinska University Hospital, Stockholm during one month
Fuentes S; Frodin J-E
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2014;45(3):1293-1303
Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients
Staff C; Mozaffari F; Frodin J-E; Mellstedt H; Liljefors M
Article: ANNALS OF ONCOLOGY. 2013;24(9):2335-2341
A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial
Johnsson A; Hagman H; Frodin J-E; Berglund A; Keldsen N; Fernebro E; Sundberg J; Christensen RDP; Spindler K-LG; Bergstrom D; Jakobsen A
Article: JOURNAL OF CLINICAL IMMUNOLOGY. 2012;32(4):855-865
Induction of IgM, IgA and IgE Antibodies in Colorectal Cancer Patients Vaccinated with a Recombinant CEA Protein
Staff C; Magnusson CGM; Hojjat-Farsangi M; Mosolits S; Liljefors M; Frodin J-E; Wahren B; Mellstedt H; Ullenhag GJ
Article: ACTA ONCOLOGICA. 2011;50(3):441-447
Clinical Phase I study with an Insulin-like Growth Factor-1 Receptor Inhibitor: Experiences in patients with squamous non-small cell lung carcinoma
Ekman S; Frodin J-E; Harmenberg J; Bergman A; Hedlund A; Dahg P; Alvfors C; Stahl B; Bergstrom S; Bergqvist M
Article: ANNALS OF ONCOLOGY. 2010;21(5):1020-1026
A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer
Glimelius B; Lahn M; Gawande S; Cleverly A; Darstein C; Musib L; Liu Y; Spindler KL; Frodin J-E; Berglund A; Bystrom P; Qvortrup C; Jakobsen A; Pfeiffer P
Article: MEDICAL ONCOLOGY. 2010;27(1):65-72
An explorative randomised phase II study of sequential chemotherapy in advanced upper gastrointestinal cancer
Berglund A; Bystrom P; Johansson B; Nygren P; Frodin J-E; Pedersen D; Letocha H; Glimelius B
Article: ANNALS OF ONCOLOGY. 2009;20(6):1057-1061
Early prediction of response to first-line chemotherapy by sequential [¹⁸F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer
Bystrom P; Berglund A; Garske U; Jacobsson H; Sundin A; Nygren P; Frodin J-E; Glimelius B
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2008;57(3):379-388
Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicity
Liljefors M; Nilsson B; Mellstedt H; Mellstedt H; Frodin J-E
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2007;56(7):973-984
A short-term dietary supplementation with high doses of vitamin E increases NK cell cytolytic activity in advanced colorectal cancer patients
Hanson MGV; Ozenci V; Carlsten MCV; Glimelius BL; Frodin J-EA; Masucci G; Malmberg K-J; Kiessling RVR
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2005;26(6):1581-1589
Clinical effects of a chimeric anti-EpCAM monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma
Liljefors M; Nilsson B; Fagerberg J; Ragnhammar P; Mellstedt H; Frödin JE
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2005;54(6):557-570
T-cell receptor BV gene usage in colorectal carcinoma patients immunised with recombinant Ep-CAM protein or anti-idiotypic antibody
Mosolits S; Markovic K; Fagerberg J; Frödin JE; Rezvany MR; Kiaii S; Mellstedt H; Jeddi-Tehrani M
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2004;25(3):703-711
Anti-EpCAM monoclonal antibody (MAb17-1A) based treatment combined with α-interferon, 5-fluorouracil and granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma
Liljefors M; Ragnhammar P; Nilsson B; Ullenhag G; Mellstedt H; Frödin JE
Article: CLINICAL CANCER RESEARCH. 2004;10(16):5391-5402
Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased response against MHC class I- and II-restricted Ep-CAM epitopes in colorectal carcinoma patients
Mosolits S; Markovic K; Frödin JE; Virving L; Magnusson CGM; Steinitz M; Fagerberg J; Mellstedt H
Article: ANTICANCER RESEARCH. 2004;24(4):2375-2383
Spectrum of cytokeratin-positive cells in the bone marrows of colorectal carcinoma patients
Shetye JD; Liljefors ML; Emdin SO; Frödin JE; Strigård K; Mellstedt HT; Porwit A
Article: CLINICAL CANCER RESEARCH. 2004;10(10):3273-3281
Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor
Ullenhag GJ; Frödin JE; Jeddi-Tehrani M; Strigård K; Eriksson E; Samanci A; Choudhury A; Nilsson B; Rossmann ED; Mosolits S; Mellstedt H
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2004;53(4):331-337
Functional HLA-DR T cell epitopes of CEA identified in patients with colorectal carcinoma immunized with the recombinant protein CEA
Ullenhag GJ; Fagerberg J; Strigård K; Frödin JE; Mellstedt H
Article: RADIOTHERAPY AND ONCOLOGY. 2004;70(2):171-175
Phase I study of UFT plus leucovorin with radiotherapy in patients with inextirpable non-rectal, gastrointestinal cancer
Byström P; Frödin JE; Berglund Å; Wilking N; Glimelius B
Article: ACTA ONCOLOGICA. 2004;43(3):276-279
A phase II study of UFT and leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer
Gyldenkerne N; Glimelius B; Frödin JE; Kjaer M; Pfeiffer P; Hansen F; Keldsen N; Sandberg E; Jakobsen A
Article: INTERNATIONAL JOURNAL OF CANCER. 2003;105(5):717-723
Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A
Liljefors M; Nilsson B; Skog ALH; Ragnhammar P; Mellstedt H; Frödin JE
Article: CLINICAL CANCER RESEARCH. 2003;9(7):2447-2456
Immunization of colorectal carcinoma patients with a recombinant Canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colonystimulating factor induced a tumor-specific cellular immune response
Ullenhag GJ; Frödin JE; Mosolits S; Kiaii S; Hassan M; Bonnet MC; Moingeon P; Mellstedt H; Rabbani H
Article: LAKARTIDNINGEN. 2003;100(26-27):2312-2313
[Palliative chemotherapy in advanced colorectal cancer can often be administered intermittently].
Glimelius B; Berglund A; Frödin J-E; Nygren P
Article: ANTICANCER RESEARCH. 2003;23(2C):1789-1794
5-FU split dose;: a phase I/II and pharmacokinetic study of a different schedule of the Nordic regimen in advanced colorectal carcinoma
Berglund A; Carlsson G; Gustavsson B; Frödin JE; Ragnhammar P; Glimelius B
Article: ANNALS OF OTOLOGY, RHINOLOGY AND LARYNGOLOGY. 2003;112(3):236-241
Decreasing incidence of malignant tumors of the paranasal sinuses in Sweden -: An analysis of 141 consecutive cases at Karolinska Hospital from 1960 to 1980
Norlander T; Frödin JE; Silfverswärd C; Änggård A
Article: ACTA ONCOLOGICA. 2003;42(5-6):416-429
Radiotherapy practices in Sweden compared to the scientific evidence
Lindholm C; Cavallin-Ståhl E; Ceberg J; Frödin JE; Littbrand B; Möller TR
Article: ACTA ONCOLOGICA. 2003;42(5-6):387-410
A prospective survey of radiotherapy practice 2001 in Sweden
Möller TR; Brorsson B; Ceberg J; Frödin JE; Lindholm C; Nylén U; Perfekt R
Article: ACTA ONCOLOGICA. 2003;42(5-6):357-365
The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of radiotherapy for cancer including a prospective survey of radiotherapy practice in Sweden 2001 -: Summary and conclusions
Ringborg U; Bergqvist D; Brorsson B; Cavallin-Ståhl E; Ceberg J; Einhorn N; Frödin JE; Järhult J; Lamnevik G; Lindholm C; Littbrand B; Norlund A; Nylén U; Rosén W; Svensson H; Möller TR
Article: ANNALS OF ONCOLOGY. 2002;13(12):1868-1873
Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer
Glimelius B; Ristamäki R; Kjaer M; Pfeiffer P; Skovsgaard T; Tveit KM; Linné T; Frödin JE; Boussard B; Oulid-Aïssa D; Pyrhönen S
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2002;51(5):255-262
Treatment with GM-CSF and IL-2 in patients with metastatic colorectal carcinoma induced high serum levels of neopterin and sIL-2R, an indicator of immune suppression
Skog ALH; Wersäll P; Ragnhammar P; Frödin JE; Mellstedt H
Article: CLINICAL CANCER RESEARCH. 2002;8(6):1772-1778
A short-term dietary supplementation of high doses of vitamin E increases T helper 1 cytokine production in patients with advanced colorectal cancer
Malmberg KJ; Lenkei R; Petersson M; Ohlum T; Ichihara F; Glimelius B; Frödin JE; Masucci G; Kiessling R
Article: HYBRIDOMA. 2002;21(2):99-101
MAb17-1A and Cytokines for the treatment of patients with colorectal carcinoma
Frödin JE; Fagerberg J; Skog ALH; Liljefors M; Ragnhammar P; Mellstedt H
Article: CANCER RESEARCH. 2002;62(5):1364-1369
Induction of IgG subclass responses in colorectal carcinoma patients vaccinated with recombinant carcinoembryonic antigen
Ullenhag GJ; Frödin JE; Strigård K; Mellstedt H; Magnusson CGM
Article: ACTA ONCOLOGICA. 2002;41(6):525-531
Dose-effect relationship of bolus 5-fluorouracil in the treatment of advanced colorectal cancer
Jakobsen A; Berglund Å; Glimelius B; Frödin JE; Hansen F; Kjær M; Madsen EL; Sandberg E; Poulsen JP; Carlsson GR; Gustavsson B
Article: CLINICAL IMMUNOLOGY. 2001;99(1):65-74
Incidence of GM-CSF antibodies in cancer patients receiving GM-CSF for immunostimulation
Ullenhag G; Bird C; Ragnhammar P; Frödin JE; Strigård K; Österborg A; Thorpe R; Mellstedt H; Wadhwa M
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 1999;48(8):463-470
Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma
Skog ALH; Ragnhammar P; Fagerberg J; Frödin JE; Goldinger M; Koldestam H; Liljefors M; Nilsson B; Shetye J; Wersäll P; Mellstedt H
Article: CLINICAL CANCER RESEARCH. 1998;4(8):1921-1929
Immunopathology of metastases in patients of colorectal carcinoma treated with monoclonal antibody 17-1A and granulocyte macrophage colony-stimulating factor
Shetye J; Ragnhammar P; Liljefors M; Christensson B; Frodin JE; Biberfeld P; Mellstedt H
Article: ACTA ONCOLOGICA. 1997;36(5):465-469
Multiple primary malignant tumors in a national cancer registry - Reliability of reporting
Frodin JE; Ericsson J; Barlow L
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 1996;42(2):81-87
Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A
Fagerberg J; Ragnhammar P; Liljefors M; Hjelm AL; Mellstedt H; Frodin JE
Article: ACTA ONCOLOGICA. 1996;35(7):70-74
Prostate cancer
Frodin JE
Article: ACTA ONCOLOGICA. 1996;35(7):46-53
Lung cancer
Frodin JE
Article: ACTA ONCOLOGICA. 1996;35(8):967-979
Radiotherapy in Sweden - A study of present use in relation to the literature and an estimate of future trends
Frodin JE; Jonsson E; Moller T; Werko L
Article: CANCER RESEARCH. 1995;55(24):6092-6096
MUTATION SCREENING IN THE HMLH1 GENE IN SWEDISH HEREDITARY NONPOLYPOSIS COLON-CANCER FAMILIES
TANNERGARD P; LIPFORD JR; KOLODNER R; FRODIN JE; NORDENSKJOLD M; LINDBLOM A
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 1995;7(5):1049-1056
DIFFERENT DOSE REGIMENS OF THE MOUSE MONOCLONAL-ANTIBODY 17-1A FOR THERAPY OF PATIENTS WITH METASTATIC COLORECTAL-CARCINOMA
RAGNHAMMAR P; FRODIN JE; HJELM AL; FAGERBERG J; WERSALL P; LINDEMALM C; NILSSON B; FOX K; MAGNUSSON I; EWERTH S; THOR K; SECHER E; MELLSTEDT H
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 1995;40(6):367-375
GRANULOCYTE MACROPHAGE-COLONY-STIMULATING FACTOR AUGMENTS THE INDUCTION OF ANTIBODIES, ESPECIALLY ANTIIDIOTYPIC ANTIBODIES, TO THERAPEUTIC MONOCLONAL-ANTIBODIES
RAGNHAMMAR P; FAGERBERG J; FRODIN JE; WERSALL P; HANSSON LO; MELLSTEDT H
Article: CANCER BIOTHERAPY. 1995;10(1):5-12
SUBCUTANEOUS INTERLEUKIN-2 AND ALPHA-INTERFERON IN ADVANCE COLORECTAL-CARCINOMA - A PHASE-II STUDY
HJELM AL; RAGNHAMMAR P; FAGERBERG J; MAGNUSSON I; FRODIN JE; SVANSTROM R; SHETYE J; MELLSTEDT H; WERSALL JP
Show more

All other publications

Corrigendum: CLINICAL CANCER RESEARCH. 2019;25(9):2939
Durable Carcinoembryonic Antigen (CEA)-Specific Humoral and Cellular Immune Responses in Colorectal Carcinoma Patients Vaccinated with Recombinant CEA and Granulocyte/Macrophage Colony-Stimulating Factor (vol 10, pg 3273, 2004)
Ullenhag GJ; Frodin J-E; Jeddi-Tehrani M; Lidstromer N; Strigard K; Eriksson E; Samanci A; Choudhury A; Nilsson B; Rossmann ED; Mosolits S; Mellstedt H
Meeting abstract: ANNALS OF ONCOLOGY. 2018;29:vi31
Molecular treatment stratification in second-line treatment of pancreatic adenocarcinoma: PePaCaKa-001
Kordes M; Lohr M; Malgerud L; Kaduthanam S; Frodin J-E; Karimi M; Yachnin J; Moro CF; Ghazi S; Heuchel R; Wirta V; Huelsewig C; Stecker K; Del Chiaro M; Ostman A; Engstrand L; Brock S; Gustafsson-Liljefors M
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2018;36(15):e16243
Palliative treatment of pancreatic adenocarcinoma in a real-world setting.
Kordes M; Malgerud O; Karimi M; Frodin J-E; Liljefors MG; Loehr M
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2018;36(15):e16214
Applying evidence-based software for NGS in pancreatic cancer: First results from the PePaCaKa study.
Loehr M; Kordes M; Malgerud L; Kaduthanam S; Frodin JE; Karimi M; Yachnin J; Moro CF; Ghazi S; Heuchel RL; Wirta V; Huelsewig C; Stecker K; Del Chiaro M; Ostman A; Lars E; Brock S; Gustavsson-Liljefors M
Meeting abstract: EUROPEAN JOURNAL OF CANCER. 2011;47:S595-S596
Phase I Dose-escalation Study of AXL1717: a Novel Targeted Oral Insulin-like Growth Factor-1 Receptor (IGF-1R) Inhibitor and Its Implications for Patients With Non-small Cell Lung Carcinoma
Ekman S; Harmenberg J; Stahl B; Hedlund A; Bergstrom S; Frodin J; Bergqvist M
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2011;29(15):3526
A randomized phase III trial on maintenance treatment with bevacizumab (bev) alone or in combination with erlotinib (erlo) after chemotherapy and bev in metastatic colorectal cancer (mCRC)
Johnsson A; Frodin J; Berglund A; Hagman H; Sundberg J; Bergstrom D; Christensen RD; Keldsen N; Spindler KG; Jakobsen AKM
Meeting abstract: CANCER RESEARCH. 2011;71:1276
A novel targeted oral insulin-like growth factor 1 (IGF-1) receptor inhibitor and its implications for patients with squamous cell lung carcinoma
Ekman S; Harmenberg J; Hedlund AJ; Bergstrom S; Frodin JE; Bergqvist M
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2010;28(15):e13019
Clinical phase I/II study with the insulin-like growth factor-1 receptor inhibitor AXL1717: Future implications for patients with squamous non-small cell lung carcinoma?
Ekman S; Frodin J; Harmenberg J; Bergman A; Hedlund A; Dahg P; Bergstrom S; Bergqvist M
Letter: ANNALS OF ONCOLOGY. 2010;21(5):1127-1128
Long-term follow-up of chemonaive patients with asymptomatic metastatic colorectal cancer treated with enzastaurin in a window of opportunity phase II study
Glimelius B; Spindler KL; Frodin J-E; Berglund A; Bystrom P; Qvortrup C; Jakobsen A; Pfeiffer P
Meeting abstract: MOLECULAR CANCER THERAPEUTICS. 2009;8(12):b256
A novel targeted oral insulin-like growth factor 1 (IGF-1) receptor inhibitor in clinical phase I/II testing
Harmenberg J; Ekman S; Bergqvist M; Frodin J-E; Larsson O; Axelson M
Published conference paper: ANNALS OF THE NEW YORK ACADEMY OF SCIENCES. 2000;910:254-261
Ga733/EpCAM as a target for passive and active specific immunotherapy in patients with colorectal carcinoma
Mellstedt H; Fagerberg J; Frödin JE; Hjelm-Skog AL; Liljefors M; Markovic K; Mosolits S; Ragnhammar P
Review: CURRENT OPINION IN HEMATOLOGY. 1999;6(3):169-175
Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors.
Mellstedt H; Fagerberg J; Frödin JE; Henriksson L; Hjelm-Skoog AL; Liljefors M; Ragnhammar P; Shetye J; Osterborg A
Review: INTERNATIONAL JOURNAL OF CANCER. 1996;:1-72
Mass screening for prostate cancer SBU - The Swedish Council on Technology Assessment in Health Care
Johansson JE; Abrahamsson PA; Adami HO; Adolfsson J; Carlsson P; Damber JE; Gustavsson O; Hallerby N; Landberg T; Marke LA; Norming U; Nyman CR; Ponten J; Rentzhog L; Vang J; Werko L; Jonsson E; Frodin JE; Hermeren G; Svardsudd K; Norlen BJ; Pettersson S; Hoisaeter PA; Gustafson R
Other: CANCER RESEARCH. 1995;55(9):1824-1827
TUMOR-REGRESSION IN MONOCLONAL ANTIBODY-TREATED PATIENTS CORRELATES WITH THE PRESENCE OF ANTI-IDIOTYPE-REACTIVE T-LYMPHOCYTES
FAGERBERG J; HJELM AL; RAGNHAMMAR P; FRODIN JE; WIGZELL H; MELLSTEDT H

Employments

Affiliated to Research, Department of Oncology-Pathology, Karolinska Institutet, 2023-2026

Degrees and Education

Docent, Karolinska institutet, 1998

Supervisor

Stina Fuentes, Adverse effects and quality of life after radiotherapy and surgery for rectal cancer - a randomized controlled trial enriched with register data, 2016

Articles

All other publications

Employments

Degrees and Education

Supervisor

News from KI

Events from KI